首页> 外文期刊>Journal of cataract and refractive surgery >Collagen crosslinking with riboflavin and ultraviolet-A in eyes with pseudophakic bullous keratopathy.
【24h】

Collagen crosslinking with riboflavin and ultraviolet-A in eyes with pseudophakic bullous keratopathy.

机译:假晶状体性大疱性角膜病变眼中胶原蛋白与核黄素和紫外线-A交联。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the safety and efficacy of corneal collagen crosslinking (CXL) in patients with painful pseudophakic bullous keratopathy (PBK). SETTING: University of Sao Paulo, Sao Paulo and Sadalla Amin Ghanem Eye Hospital, Joinville, Santa Catarina, Brazil. METHODS: This prospective study included consecutive eyes with PBK that had CXL. After a 9.0 mm epithelial removal, riboflavin 0.1% with dextran 20% was applied for 30 minutes followed by ultraviolet-A irradiation (370 nm, 3 mW/cm(2)). Therapeutic contact lenses were placed for 1 week. Corneal transparency, central corneal thickness (CCT), and ocular pain were assessed preoperatively and 1 and 6 months postoperatively. Statistical analysis was by paired t tests. RESULTS: Fourteen patients (14 eyes) with a mean age 71.14 years +/- 11.70 (SD) (range 53 to 89 years) were enrolled. Corneal transparency was better in all eyes 1 month after surgery. At 6 months, corneal transparency was similar to preoperative levels (P = .218). The mean CCT was 747 mum preoperatively and 623 mum at 1 month; the decrease was statistically significant (P<.001). At 6 months, the mean CCT increased to 710 mum, still significantly thinner than preoperatively (P = .006). Pain scores at 6 months were not significantly different than preoperatively (P = .066). CONCLUSIONS: Corneal CXL significantly improved corneal transparency, corneal thickness, and ocular pain 1 month postoperatively. However, it did not seem to have a long-lasting effect in decreasing pain and maintaining corneal transparency in patients with PBK.
机译:目的:评估角膜胶原交联(CXL)在疼痛性假晶状体大疱性角膜病变(PBK)患者中的安全性和有效性。地点:巴西圣保罗卡塔维纳省圣保罗大学,圣保罗大学和萨达拉·阿明·加纳姆眼科医院。方法:这项前瞻性研究包括连续眼睛患有CXL的PBK。在9.0 mm的上皮去除后,将0.1%的核黄素与20%的右旋糖酐一起使用30分钟,然后进行紫外线A照射(370 nm,3 mW / cm(2))。治疗性隐形眼镜放置1周。术前以及术后1个月和6个月评估了角膜透明度,中央角膜厚度(CCT)和眼痛。统计分析采用配对t检验。结果:纳入平均年龄为71.14岁+/- 11.70(SD)(范围为53至89岁)的14例患者(14眼)。术后1个月,所有眼睛的角膜透明度都更好。在6个月时,角膜透明度与术前水平相似(P = .218)。术前平均CCT为747 mm,1个月时为623 mm;下降具有统计学意义(P <.001)。在6个月时,平均CCT增加到710毫米,仍然比术前明显薄(P = .006)。 6个月时的疼痛评分与术前无显着差异(P = .066)。结论:术后1个月,角膜CXL显着改善了角膜透明度,角膜厚度和眼痛。但是,在减轻PBK患者的疼痛和保持角膜透明性方面似乎没有持久的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号